Evoke Pharma (EVOK) Q3 2024 earnings summary

Executive summary

• Net product sales for Q3 2024 were $2.7M, up 70% year-over-year, driven by increased adoption and expanded pharmacy networks.

• Cash and cash equivalents stood at $11.3M as of September 30, 2024, with ongoing losses and a going concern warning due to insufficient funds for 12 months.

• The company remains dependent on Gimoti sales and faces substantial doubt about its ability to continue as a going concern without additional financing.

• Regained compliance with Nasdaq's equity and minimum bid price requirements after a reverse stock split and equity financings.

Financial highlights

• Q3 2024 net product sales: $2.7M (up from $1.6M in Q3 2023); nine-month sales: $6.9M (up from $3.5M year-over-year).

• Net loss for Q3 2024: $1.3M (improved from $1.7M in Q3 2023); nine-month net loss: $4.2M (improved from $5.8M year-over-year).

• Operating expenses for Q3 2024: $3.9M, up 24% year-over-year, mainly due to higher marketing and Eversana profit sharing.

• Cash used in operations for nine months: $4.2M; cash provided by financing activities: $10.8M.

Outlook and guidance

• Current cash is expected to fund operations into Q4 2025, but additional capital will be needed to continue as a going concern.

• Ongoing focus on Gimoti commercialization, post-marketing clinical trial, and potential expansion of indications.